ALXO

ALX Oncology Holdings Inc. Common Stock

1.86

USD

ALXO Earnings Reports

Positive Surprise Ratio

ALXO beat 12 of 23 last estimates.

52%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$0.22

Implied change from Q4 25 (Revenue/ EPS)

-40.54%

Implied change from Q1 25 (Revenue/ EPS)

-61.40%

ALX Oncology Holdings Inc. Common Stock earnings per share and revenue

On Feb 27, 2026, ALXO reported earnings of -0.37 USD per share (EPS) for Q4 25, missing the estimate of -0.36 USD, resulting in a -0.08% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -10.21% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.22 USD, with revenue projected to reach -- USD, implying an decrease of -40.54% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Humacyte, Inc. Common Stock

Report Date

Mar 27, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.13

Surprise

+3.20%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Entera Bio Ltd. Ordinary Shares

Report Date

Mar 27, 2026 For Q4 25

Estimate

-$0.09

Actual

-$0.07

Surprise

+23.75%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were ALX Oncology Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, ALX Oncology Holdings Inc. Common Stock reported EPS of -$0.37, missing estimates by -0.08%, and revenue of $0.00, 0% as expectations.

How did the market react to ALX Oncology Holdings Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -10.21%, changed from $2.35 before the earnings release to $2.11 the day after.

When is ALX Oncology Holdings Inc. Common Stock expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for ALX Oncology Holdings Inc. Common Stock's next earnings report?

Based on 6 analysts, ALX Oncology Holdings Inc. Common Stock is expected to report EPS of -$0.22 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.